Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →'The Alpharadin deal with Bayer totals up to $800 million (EUR560m) to Algeta.' 'In Bayer we have selected a world-class oncology company with a proven global…
Algeta and Bayer signed a 2009 development and commercialization agreement valued at $800M for Xofigo globally; Bayer fully acquired Algeta for $2.9B in March…
Xofigo's EU marketing authorization for CRPC patients with symptomatic bone metastases positions it as a unique bone-targeted alpha-radiotherapy with a…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Co-development/commercialization of radium-223 (Xofigo) for CRPC bone mets. ~$800M deal value. Source: Bayer/Algeta press, Norway business publications.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Algeta ASA (this deal) | 2009 | $800M | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2009 deals · Bayer AG deals